Themis Medicare Standalone March 2023 Net Sales at Rs 80.10 crore, up 0.39% Y-o-Y

Themis Medicare rose 1.67% to Rs 1,366.05 after the company announced that it has received an approval from the Drug Controller General of India (DCGI) for import & marketing of Remifentanil Hydrochloride injection.

Themis Medicare gains on DCGI nod for Remifentanil injection

Stocks to watch before going into trade today

Stocks To Watch: Reliance Industries, Advanced Enzyme, NTPC, Themis Medicare

Themis Medicare consolidated net profit declines 7.78% in the September 2022 quarter

Buzzing stocks: Airtel, NTPC, YES Bank, Themis Medicare, Britannia, Disa India, Nykaa, Quess Corp

Stocks that will see action today (Oct 7)

Tera Software Ltd, Anjani Portland Cement Ltd, BSL Ltd and Suryoday Small Finance Bank Ltd are among the other gainers in the BSE’s ‘B’ group today, 09 September 2022.

Themis Medicare Ltd leads gainers in ‘B’ group

Themis Medicare consolidated net profit declines 44.23% in the June 2022 quarter

VIRALEX (Inosine Pranobex) is an immunomodulatory agent with broad spectrum antiviral properties.

Themis Medicare gets add on approval for drug VIRALEX; Stock plunges over 5%

Themis Medicare rose 3.37% to Rs 857.80 after the company announced the add on approval for drug “Viralex” by the Drug Controller General of India (DCGI).

Themis Medicare climbs after Viralex gets add on approval from DCGI

Mumbai-based pharmaceutical company Themis Medicares anti-viral drug Viralex has received Drugs Controller General of Indias (DCGI) approval, the company informed the stock exchange on Monday.

Themis Medicare’s anti-viral COVID drug gets DCGI nod

Enhances both innate & adaptive immunity and strengthens body’s immune response to viral infections In a landmark development for the treatment of COVID-19, Themis Medicare Ltd. (Themis), - Mediawire

Themis gets Drug Controller’s nod to launch Inosine Pranobex a novel medicine to treat Covid19, A Viral Infection

Price return has been average, nothing exciting

Performance

Seems to be overvalued vs the market average

Valuation

Financials growth has been moderate for a few years

Growth

Showing good signs of profitability & efficiency

Profitability

The stock is underpriced and is not in the overbought zone

Current price is less than the intrinsic value

Fundamentals

Good time to consider, stock is not in the overbought zone

Technicals

Entry point

Promoter pledged holding

Unsolicited messages

Default probability

Red flags

Themis Medicare Limited is engaged in manufacturing pharmaceuticals and medicinal chemicals, such as formulations and active pharmaceutical ingredients.

Themis Medicare Ltd